Developments in the systemic therapy of early-stage breast cancer

European Journal of Cancer, Supplement

Volumn 5, Issue 1, 2007, Pages 3-10

  O'Shaughnessy, Joyce ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adjuvant; Chemotherapy; Disease free survival; Early stage breast cancer; HER2; Hormonal therapy; Oestrogen receptor; Predictive factors; Prognostic factors

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GAMMA UROGASTRONE; GEMCITABINE; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DRUG DOSE ESCALATION; FEBRILE NEUTROPENIA; HUMAN; HYPOTHESIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RESEARCH PRIORITY; RETROSPECTIVE STUDY; SYSTEMIC THERAPY;

EID: 34249070773     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(07)70009-5     Document Type: Article

References (31)

1. Sørlie T., Perou C., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 (2001) 10869-10874
2. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
3. Goldhirsch A., Glick J., Gelber R., Coates A., Thurlimann B., and Senn H. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
4. Paik S. Molecular profiling of breast cancer. Curr Opin Obstet Gynecol 18 (2006) 59-63
5. Fisher B., Jeong J., Bryant J., et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer:long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364 (2004) 858-868
6. International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 94 (2002) 1054-1065
7. Wolff A., and Abeloff M. Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: It ain't necessarily so. J Natl Can Inst 94 (2002) 1041-1043
8. Albain K., Barlow W., O'Malley F., et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer:mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat 88 Suppl 1 (2004) [abstract 37]
9. Berry D., Cirrincione C., Henderson I., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295 (2006) 1658-1667
10. Pritchard K., Shepherd L., O'Malley F., et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354 (2006) 2103-2111
11. O'Malley F., Chia S., Tu D., et al. Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA. 5). J Clin Oncol 24 Suppl 18S (2006) 533
12. Knoop A., Knudsen H., Balslev E., et al. TOP2A aberrations as predictive and prognostic marker in high-risk breast cancer patients. A randomized DBCG Trial (DBCG89D). J Clin Oncol 24 Suppl 18S (2006) 532
13. Zambetti M., Moliterni A., Materazzo C., et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 19 (2001) 37-43
14. Jensen B. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 33 3 Suppl 8 (2006) S15-S21
15. Giordano S., Pinder M., Duan Z., Hortobagyi G., and Goodwin J. Congestive heart failure in older women treated with anthracycline chemotherapy. Proc Am Soc Clin Oncol 24 (2006) 8s [abstract 521]
16. Shepherd L., Parulekar W., Pritchard K., et al. Left ventricular function following adjuvant chemotherapy for breast cancer:the NIC CTG MA5 experience. Proc Am Soc Clin Oncol 24 (2006) 8s [abstract 522]
17. Bonneterre J., Roche H., Kerbrat P., et al. Long-term cardiac follow-up in relapse-free patients after six courses of uorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 22 (2004) 3070-3079
18. Jones S., Savin M., Holmes F., et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. Breast Cancer Res Treat 95 Suppl S20 (2005) [abstract 40]
19. Goldstein L., O'fNeill A., Sparano J., et al. E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol 23 Suppl 16S (2005) 512
20. Albain K., Nag S., Calderillo-Ruiz G., et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol 22 Suppl 14S (2004) 510
21. Poole C. Adjuvant chemotherapy for early-stage breast cancer:the tAnGo trial. Oncology (Williston Park) 18 Suppl 12 (2004) 23-26
22. Slamon D., Eiermann W., Robert N., et al. BCIRG 006: Second interim analysis. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC →T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC →TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients. Breast Cancer Res Treat 100 Suppl 1 (2006) [abstract 52]
23. Joensuu H., Kellokumpu-Lehtinen P.-L., Bono P., et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer:the FinHer Trial. Breast Cancer Res Treat 94 Suppl 1 (2005) S5 [abstract 2]
24. Joensuu H., Kellokumpu-Lehtinen P., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
25. Piccart-Gebhart M., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
26. Romond E., Perez E., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
27. Geyer C., Bryant J., Romond E., et al. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) → paclitaxel (T) vs. AC →T with trastuzumab (H). J Clin Oncol 24 Suppl 18S (2006) 581
28. Goss P., Ingle J., Palmer M., Shepherd L., and Tu D. Updated analysis of NCIC CTG MA. 17 (letrozole vs. placebo to letrozole vs. placebo) post unblinding. Breast Cancer Res Treat 94 Suppl 1 (2005) S10 [abstract 16]
29. Goss P., Ingle J., and Tu D. NCIC CTG MA. 17:disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor. Breast Cancer Res Treat 94 Suppl 1 (2005) Poster 2042
30. Ingle J., Goss P., and Tu D. Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA. 17. Breast Cancer Res Treat 94 Suppl 1 (2005) S11 [abstract 17]
31. Cui X., Schiff R., Arpino G., Osborne C., and Lee A. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23 (2005) 7721-7735